Immuno-genomic-radiomics to predict response of biliary tract cancer to camrelizumab plus GEMOX in a single-arm phase II trial

por Liu, Qiu-Ping, Tang, Jie, Chen, Yi-Zhang, Guo, Fen, Ma, Ling, Pan, Lan-Lan, Tian, Yi-Tong, Wu, Xiao-Feng, Zhang, Yu-Dong, Chen, Xiao-Feng
Publicado 2023